The Europe animal health market size was estimated at USD 18.0 billion in 2025 and is projected to reach USD 39.9 billion by 2033, growing at a CAGR of 10.6% from 2026 to 2033. The industry is experiencing growth driven by the rising prevalence of zoonotic and infectious diseases, the growth of the companion animal population and pet humanization,advancements in veterinary pharmaceuticals and biologics, and regulatory support and food safety standards.
Increasing outbreaks of zoonotic and infectious diseases have raised concerns across Europe’s livestock and companion animal sectors. According to the French Agricultural Research Centre for International Development CIRAD, France has faced bluetongue virus (BTV) and epizootic hemorrhagic disease (EHD) outbreaks in 2023, with a new BTV strain spreading across Europe in 2024. This growing disease burden drives demand for advanced vaccines, diagnostics, and preventive solutions to ensure biosecurity and herd protection. This leads to greater investment in veterinary pharmaceuticals, surveillance systems, and R&D initiatives. Thus, companies and governments are prioritizing disease control strategies, strengthening the animal health market across Europe. Furthermore, lumpy skin disease (LSD) outbreaks have further intensified disease control efforts, with Spain confirming its 18th outbreak in Girona on 07 January 2026 and France reporting a new case in Pamiers, Ariège, on 02 January 2026, resulting in full culling of 113 susceptible animals. Conversely, Italy's Sardinia successfully eliminated LSD as of 07 January 2026 following a mandatory vaccination campaign covering approximately 300,000 cattle, recording zero active cases nationwide. These divergent outcomes across Europe continue to support the need for robust veterinary interventions, vaccination strategies, and disease surveillance infrastructure.
The rising pet ownership has increased demand for sophisticated veterinary treatment throughout Europe, strengthened by cultural movements toward pet humanization. Pet owners see their pets as part of the family rather than as possessions, thus increasing their expenditure on high-quality food, health programs, and preventative care. According to the Animal Health Europe report, the region places a high priority on caring for companion animals, as evidenced by the 28 billion euros spent on pet food, 25 billion on pet-related goods and services, and 4 billion on animal medications. Increased use of parasiticides, veterinary medications, diagnostic testing, and wellness products is fueled by this trend. Access to high-quality treatment is further supported by the prevalence of pet insurance in countries like the UK, Sweden, and Germany. As a result, the companion animal health sector is becoming one of the most dynamic growth areas, boosting overall market expansion.
Continuous R&D investment in veterinary pharmaceuticals, vaccines, and biologics has enhanced treatment and prevention options for both livestock and companion animals. Disease management is changing as a result of innovations including next-generation vaccinations, long-acting injectable, and monoclonal antibodies. As per the report of Animal Health Europe, the animal medicines industry invested over USD 649 million in R&D in 2024. Similarly, in 2024, the European Medicines Agency authorized 25 new animal health products for veterinary use. These advancements improve treatment efficacy, reduce resistance issues, and expand preventive healthcare adoption. Companies introducing innovative therapies gain a strong competitive advantage, improving overall herd and pet health outcomes. This accelerates demand for biologics and pharmaceutical products, increasing steady revenue growth and strengthening the innovation pipeline in Europe’s animal health industry.
This product will be delivered within 1-3 business days.
Increasing outbreaks of zoonotic and infectious diseases have raised concerns across Europe’s livestock and companion animal sectors. According to the French Agricultural Research Centre for International Development CIRAD, France has faced bluetongue virus (BTV) and epizootic hemorrhagic disease (EHD) outbreaks in 2023, with a new BTV strain spreading across Europe in 2024. This growing disease burden drives demand for advanced vaccines, diagnostics, and preventive solutions to ensure biosecurity and herd protection. This leads to greater investment in veterinary pharmaceuticals, surveillance systems, and R&D initiatives. Thus, companies and governments are prioritizing disease control strategies, strengthening the animal health market across Europe. Furthermore, lumpy skin disease (LSD) outbreaks have further intensified disease control efforts, with Spain confirming its 18th outbreak in Girona on 07 January 2026 and France reporting a new case in Pamiers, Ariège, on 02 January 2026, resulting in full culling of 113 susceptible animals. Conversely, Italy's Sardinia successfully eliminated LSD as of 07 January 2026 following a mandatory vaccination campaign covering approximately 300,000 cattle, recording zero active cases nationwide. These divergent outcomes across Europe continue to support the need for robust veterinary interventions, vaccination strategies, and disease surveillance infrastructure.
The rising pet ownership has increased demand for sophisticated veterinary treatment throughout Europe, strengthened by cultural movements toward pet humanization. Pet owners see their pets as part of the family rather than as possessions, thus increasing their expenditure on high-quality food, health programs, and preventative care. According to the Animal Health Europe report, the region places a high priority on caring for companion animals, as evidenced by the 28 billion euros spent on pet food, 25 billion on pet-related goods and services, and 4 billion on animal medications. Increased use of parasiticides, veterinary medications, diagnostic testing, and wellness products is fueled by this trend. Access to high-quality treatment is further supported by the prevalence of pet insurance in countries like the UK, Sweden, and Germany. As a result, the companion animal health sector is becoming one of the most dynamic growth areas, boosting overall market expansion.
Continuous R&D investment in veterinary pharmaceuticals, vaccines, and biologics has enhanced treatment and prevention options for both livestock and companion animals. Disease management is changing as a result of innovations including next-generation vaccinations, long-acting injectable, and monoclonal antibodies. As per the report of Animal Health Europe, the animal medicines industry invested over USD 649 million in R&D in 2024. Similarly, in 2024, the European Medicines Agency authorized 25 new animal health products for veterinary use. These advancements improve treatment efficacy, reduce resistance issues, and expand preventive healthcare adoption. Companies introducing innovative therapies gain a strong competitive advantage, improving overall herd and pet health outcomes. This accelerates demand for biologics and pharmaceutical products, increasing steady revenue growth and strengthening the innovation pipeline in Europe’s animal health industry.
Europe Animal Health Market Report Segmentation
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Europe animal health market report based on product, animal type, distribution channel, end-use, and country.Product Outlook (Revenue, USD Million, 2021-2033)
- Biologics
- Vaccines
- Modified/ Attenuated Live
- Inactivated (Killed)
- Other Vaccines
- Other Biologics
- Pharmaceuticals
- Parasiticides
- Anti-infectives
- Anti-inflammatory
- Analgesics
- Others
- Diagnostics
- Consumables, reagents and kits
- Instruments and devices
- Equipment & Disposables
- Critical Care Consumables
- Anesthesia Equipment
- Fluid Management Equipment
- Temperature Management Equipment
- Rescue & Resuscitation Equipment
- Research Equipment
- Patient Monitoring Equipment
- Medicinal Feed Additives
- Others
- Veterinary Telehealth
- Veterinary Software
- Livestock Monitoring
Animal Type Outlook (Revenue, USD Million, 2021-2033)
- Production Animals
- Poultry
- Swine
- Cattle
- Sheep & Goats
- Fish
- Companion Animals
- Dogs
- Cats
- Horses
- Others
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Retail
- E-Commerce
- Hospital/ Clinic Pharmacy
End-use Outlook (Revenue, USD Million, 2021-2033)
- Veterinary Reference Laboratories
- Point-of-care Testing/In-house Testing
- Veterinary Hospitals & Clinics
- Others
Country Outlook (Revenue, USD Million, 2021-2033)
- UK
- Germany
- France
- Italy
- Spain
- Russia
- Netherlands
- Switzerland
- Sweden
- Ireland
- Poland
- Denmark
- Norway
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Europe Animal Health Market Variables, Trends, & Scope
Chapter 4. Europe Animal Health Market: Product Estimates & Trend Analysis
Chapter 5. Europe Animal Health Market: Distribution Channel Estimates & Trend Analysis
Chapter 6. Animal Health Market: Animal Type Estimates & Trend Analysis
Chapter 7. Europe Animal Health Market: End Use Estimates & Trend Analysis
Chapter 8. Europe Animal Health Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Ceva
- Vetoquinol S.A.
- Boehringer Ingelheim International GmbH
- Virbac
- B. Braun Vet Care
- Dechra Pharmaceuticals PLC
- Bimed Inc.
- Zoetic Inc.
- Elanco
- IDEXX Laboratories, Inc.
- MSD Animal Health
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 18 Billion |
| Forecasted Market Value ( USD | $ 39.9 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 11 |
